259 related articles for article (PubMed ID: 26370222)
1. Use of best-worst scaling to assess patient perceptions of treatments for refractory overactive bladder.
Beusterien K; Kennelly MJ; Bridges JF; Amos K; Williams MJ; Vasavada S
Neurourol Urodyn; 2016 Nov; 35(8):1028-1033. PubMed ID: 26370222
[TBL] [Abstract][Full Text] [Related]
2. Patient preferences for treating refractory overactive bladder in the UK.
Hashim H; Beusterien K; Bridges JF; Amos K; Cardozo L
Int Urol Nephrol; 2015 Oct; 47(10):1619-27. PubMed ID: 26347077
[TBL] [Abstract][Full Text] [Related]
3. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator.
Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J
Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786
[TBL] [Abstract][Full Text] [Related]
4. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
[TBL] [Abstract][Full Text] [Related]
5. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
[TBL] [Abstract][Full Text] [Related]
6. Management of refractory idiopathic overactive bladder: intradetrusor injection of botulinum toxin type A versus posterior tibial nerve stimulation.
Sherif H; Khalil M; Omar R
Can J Urol; 2017 Jun; 24(3):8838-8846. PubMed ID: 28646940
[TBL] [Abstract][Full Text] [Related]
7. Management of Idiopathic Overactive Bladder Syndrome: What Is the Optimal Strategy After Failure of Conservative Treatment?
Marcelissen T; Cornu JN; Antunes-Lopes T; Geavlete B; Delongchamps NB; Rashid T; Rieken M; Rahnama'i MS
Eur Urol Focus; 2018 Sep; 4(5):760-767. PubMed ID: 29807823
[TBL] [Abstract][Full Text] [Related]
8. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
Tubaro A; Puccini F; De Nunzio C
Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of BTX-A and neuromodulation in treating OAB with or without detrusor overactivity: a systematic review.
Rachaneni S; Latthe P
Int Urogynecol J; 2017 Jun; 28(6):805-816. PubMed ID: 28083714
[TBL] [Abstract][Full Text] [Related]
10. An analysis of factors that influence patient preference of third-line therapy for overactive bladder.
Kapur A; Harandi AA; Cohen T; Ruan H; Dabrowski C; Anderson R; Hwang K; Lee E; Weissbart S; Kim J
Neurourol Urodyn; 2022 Nov; 41(8):1906-1913. PubMed ID: 36104866
[TBL] [Abstract][Full Text] [Related]
11. Comparing the Efficacy of OnabotulinumtoxinA, Sacral Neuromodulation, and Peripheral Tibial Nerve Stimulation as Third Line Treatment for the Management of Overactive Bladder Symptoms in Adults: Systematic Review and Network Meta-Analysis.
Lo CW; Wu MY; Yang SS; Jaw FS; Chang SJ
Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32085542
[TBL] [Abstract][Full Text] [Related]
12. Overactive Bladder.
White N; Iglesia CB
Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
[TBL] [Abstract][Full Text] [Related]
13. How can we better manage drug-resistant OAB/DO? ICI-RS 2018.
Chermansky C; Schurch B; Rahnama'i MS; Averbeck MA; Malde S; Mancini V; Valentini F; Sahai A
Neurourol Urodyn; 2019 Dec; 38 Suppl 5():S46-S55. PubMed ID: 31821628
[TBL] [Abstract][Full Text] [Related]
14. Percutaneous Tibial Nerve Stimulation Improves Female Sexual Function in Women With Overactive Bladder Syndrome.
Musco S; Serati M; Lombardi G; Lumi E; Parisi AI; Del Popolo G; Finazzi Agrò E
J Sex Med; 2016 Feb; 13(2):238-42. PubMed ID: 26803455
[TBL] [Abstract][Full Text] [Related]
15. [Second-line therapy of idiopathic detrusor overactivity. Sacral neuromodulation and botulinum toxin A].
Amend B; Castro-Diaz D; Chartier-Kastler E; De Ridder D; Everaert K; Spinelli M; van Kereebroeck P; Sievert KD
Urologe A; 2010 Feb; 49(2):245-52. PubMed ID: 19859688
[TBL] [Abstract][Full Text] [Related]
16. [Neuromodulation as a treatment for overactive bladder syndrome].
Smits MA; Marcelissen TA; van Kerrebroeck PE; de Wachter SG
Ned Tijdschr Geneeskd; 2012; 156(33):A4135. PubMed ID: 22894803
[TBL] [Abstract][Full Text] [Related]
17. What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?
Zahner PM; Giusto LL; Goldman HB
Curr Urol Rep; 2018 Sep; 19(11):91. PubMed ID: 30196438
[TBL] [Abstract][Full Text] [Related]
18. What Is New in Neuromodulation for Overactive Bladder?
Tutolo M; Ammirati E; Van der Aa F
Eur Urol Focus; 2018 Jan; 4(1):49-53. PubMed ID: 29773501
[TBL] [Abstract][Full Text] [Related]
19. Screening for depression and anxiety in patients with storage or voiding dysfunction: A retrospective cohort study predicting outcome of sacral neuromodulation.
Drossaerts J; Vrijens D; Leue C; Schilders I; Van Kerrebroeck P; van Koeveringe G
Neurourol Urodyn; 2016 Nov; 35(8):1011-1016. PubMed ID: 26351817
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of overactive bladder treatments: from the US payer perspective.
Murray B; Hessami SH; Gultyaev D; Lister J; Dmochowski R; Gillard KK; Stanisic S; Tung A; Boer R; Kaplan S
J Comp Eff Res; 2019 Jan; 8(1):61-71. PubMed ID: 30511584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
